InsiderTrades.com logo
The World's First "$20 Trillion Drug?"
From Behind the Markets   |   Ad
One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!
Get the name of the stock here >>>
Gagan Dhingra net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Gagan Dhingra Biography and Net Worth

CAO of Anaplan
Gagan Dhingra is Chief Accounting Officer & Controller of Anaplan, Inc.

What is Gagan Dhingra's net worth?

The estimated net worth of Gagan Dhingra is at least $288,951.82 as of June 11th, 2021. Mr. Dhingra owns 4,534 shares of Anaplan stock worth more than $288,952 as of April 25th. This net worth evaluation does not reflect any other assets that Mr. Dhingra may own. Learn More about Gagan Dhingra's net worth.

How do I contact Gagan Dhingra?

The corporate mailing address for Mr. Dhingra and other Anaplan executives is 50 HAWTHORNE STREET, SAN FRANCISCO CA, 94105. Anaplan can also be reached via phone at (415) 742-8199 and via email at [email protected]. Learn More on Gagan Dhingra's contact information.

Has Gagan Dhingra been buying or selling shares of Anaplan?

Gagan Dhingra has not been actively trading shares of Anaplan during the past quarter. Most recently, Gagan Dhingra sold 863 shares of the business's stock in a transaction on Monday, December 13th. The shares were sold at an average price of $45.26, for a transaction totalling $39,059.38. Learn More on Gagan Dhingra's trading history.

Who are Anaplan's active insiders?

Anaplan's insider roster includes Frank Calderoni (CEO), Gagan Dhingra (CAO), Sandesh Kaveripatnam (Director), Vikas Mehta (CFO), Ana Pinczuk (Insider), and William Schuh (CRO). Learn More on Anaplan's active insiders.

Gagan Dhingra Insider Trading History at Anaplan

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/13/2021Sell863$45.26$39,059.38View SEC Filing Icon  
9/14/2021Sell870$64.94$56,497.80View SEC Filing Icon  
9/1/2021Sell2,000$70.00$140,000.00View SEC Filing Icon  
6/11/2021Sell863$51.81$44,712.034,534View SEC Filing Icon  
3/11/2021Sell812$55.47$45,041.643,379View SEC Filing Icon  
1/15/2021Sell4,000$71.68$286,720.00View SEC Filing Icon  
12/11/2020Sell722$67.17$48,496.745,612View SEC Filing Icon  
9/11/2020Sell405$55.79$22,594.954,882View SEC Filing Icon  
6/11/2020Sell1,921$44.81$86,080.01View SEC Filing Icon  
See Full Table

Gagan Dhingra Buying and Selling Activity at Anaplan

This chart shows Gagan Dhingra's buying and selling at Anaplan by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Anaplan Company Overview

Anaplan logo
Anaplan, Inc. provides a cloud-based connected planning platform to connect organizations and people in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Its platform in-memory data storage and calculation capabilities deliver calculations of data in real time and provide a single source of information for planning, ensuring the consistency, quality, and integrity of the data utilized across the enterprise. The company delivers its application over the Internet as a subscription service using a software-as-a-service model, as well as offers professional services related to implementing and supporting its application. It serves banking, capital markets, consumer products, healthcare, insurance, life science, media, professional services, retail, technology, telecom, and transportation industries, as well as government agencies. Anaplan, Inc. was founded in 2008 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $63.73
Low: $63.73
High: $63.73

50 Day Range

MA: $64.11
Low: $63.05
High: $65.80

2 Week Range

Now: $63.73
Low: $39.92
High: $70.25

Volume

N/A

Average Volume

5,787,143 shs

Market Capitalization

$9.59 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.77
The World's First "$20 Trillion Drug?"
From Behind the Markets   |   Ad
One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!
Get the name of the stock here >>>